Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I.
about
Killer immunoglobulin-like receptors and tumor immunityDownregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain.Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR).Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunityCross-presentation of tumour antigens: evaluation of threshold, duration, distribution and regulation.Heterogeneity in expression of human leukocyte antigens and melanoma-associated antigens in advanced melanoma.Innovations and strategies for the development of anticancer vaccines.Assumptions of the tumor 'escape' hypothesis.Cancer vaccines: progress reveals new complexities.Propanil exposure induces delayed but sustained abrogation of cell-mediated immunity through direct interference with cytotoxic T-lymphocyte effectors.Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells.IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases.Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens.Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapyLocus-specific analysis of human leukocyte antigen class I expression in melanoma cell linesImmune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes.Enhancing the recognition of tumour associated antigens.Homologous Prime-Boost Vaccination with OVA Entrapped in Self-Adjuvanting Archaeosomes Induces High Numbers of OVA-Specific CD8⁺ T Cells that Protect Against Subcutaneous B16-OVA Melanoma.The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced toleranceThe use of agonistic anti-CD40 therapy in treatments for cancer.Novel "Elements" of Immune Suppression within the Tumor Microenvironment.Comparison of HPV DNA vaccines employing intracellular targeting strategies.Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy.Role of Fas ligand expression in promoting escape from immune rejection in a spontaneous tumor model.Identification of CCAAT displacement protein (CDP/cut) as a locus-specific repressor of major histocompatibility complex gene expression in human tumor cells.CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination.Human dendritic cells genetically engineered to express cytosolically retained fragment of prostate-specific membrane antigen prime cytotoxic T-cell responses to multiple epitopes.The Use of Anti-CD40 mAb in Cancer.Enhanced MHC class I and costimulatory molecules on B16F10 cells by Ganoderma lucidum polysaccharides.Identification of neoepitopes recognized by tumor-infiltrating lymphocytes (TILs) from patients with glioma.
P2860
Q27005792-0B2D143E-7FFC-4233-9315-6981A0533782Q31148056-AC0B3C53-27B4-4622-BD17-5F5FFB1EBA6BQ33672480-C59B9A31-D0BF-4C0B-B00A-6C1B1E4A08DCQ33708572-06DB53D0-4446-4353-94DE-9482B7D89236Q33778847-4CBC55E2-499D-47DE-B833-35AC55112E19Q33827463-3969007E-EB0C-4FBA-A9DC-3B268B7EE190Q34182039-45A90B35-BAD3-4959-9DCE-39BFF4BC9898Q34583258-86894BF1-B8AC-4D43-924A-4D7F5D472D8FQ34774541-B7D5FDF5-E5C3-4B61-A104-F849A04A7953Q34804546-0B65D6BB-CC03-4DEC-8FBA-89A041B28813Q35638571-C6FF1532-3969-48C8-8FAA-1C24845CCA7CQ36091993-4647488B-C6F7-42FE-8C6A-7F333D363027Q36367205-9A12F3A4-6A46-46ED-8419-3AE3F4F947EBQ36470726-B4F7CCCC-ADD8-441B-8C7D-CD16B08E9D29Q36922798-DA664594-3DA9-4B28-A6AF-1EDEF3EE8ABDQ37094888-3251843D-904C-4717-84A6-8CF1FFE3B883Q37391100-B569BCAB-862E-4D5B-9980-0FC964F04285Q37539236-ACA782B4-F20E-41C3-A0B5-95590AADDE32Q37959968-DBC41099-415F-4FAC-A197-E377AD8793A9Q38026924-0229DA7B-9826-47CD-A936-2D357D79124AQ39347426-945846B8-7ADD-4997-8AE3-D5C56D2DF347Q40529159-8A44E291-A933-4A58-8840-17B93E367991Q41455932-8FEC7690-7EA7-40F4-BF49-257CDDD001F5Q42831158-12ED2B7B-EF39-4EAA-942D-ACA1EE507C96Q44878113-2A761FFF-2638-41DA-989F-4E4A5BAB01D4Q45864088-94144650-706A-4D6E-8182-03B60FBF7517Q51724569-1EC6F26F-4F13-4997-9999-E5523DA8F803Q53321210-82B97B09-D88F-405C-85A0-2411BE00581DQ54305225-298148E8-F964-4790-9F35-08C3D2AD1360Q55118347-191A6489-D7C1-4F39-BA97-14BAFE0FEAF5
P2860
Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Molecular mechanisms used by t ...... compatibility complex class I.
@en
type
label
Molecular mechanisms used by t ...... compatibility complex class I.
@en
prefLabel
Molecular mechanisms used by t ...... compatibility complex class I.
@en
P2093
P2860
P1476
Molecular mechanisms used by t ...... compatibility complex class I.
@en
P2093
A Taggarse
F Esquivel
F Marincola
N P Restifo
P Shamamian
S A Rosenberg
Y Kawakami
P2860
P304
P356
10.1097/00002371-199310000-00004
P577
1993-10-01T00:00:00Z